NCT01037790
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer No drug interventions treatment 2 completed NCT03768479
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer No drug interventions other Not Available unknown_status NCT02235051
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors No drug interventions prevention Not Available completed NCT03962647
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer treatment 0 active_not_recruiting NCT01394211
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer treatment 2 terminated NCT06439693
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT02273752
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer treatment 2 terminated NCT02015559
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus No drug interventions supportive_care 2 completed NCT01339442
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer treatment 1 completed NCT00003199
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer treatment 2 completed NCT01824836
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) supportive_care Not Available active_not_recruiting NCT00057941
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer treatment 2 completed NCT01208441
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer treatment 1 terminated NCT01368263
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer treatment 2 terminated NCT00676663
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer No drug interventions treatment 2 completed NCT03633331
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer treatment 2 unknown_status NCT00952731
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ No drug interventions treatment 2 completed NCT05020860
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer treatment 2 recruiting NCT04597580
Personalised Disease Monitoring in Metastatic Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT01385280
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer treatment Not Available completed NCT02957968
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca No drug interventions treatment 2 active_not_recruiting NCT00082810
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer treatment 2 completed NCT00602043
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer No drug interventions diagnostic 2 completed NCT00194779
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery treatment 2 completed NCT01409811
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid No drug interventions treatment Not Available terminated NCT01791478
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer No drug interventions treatment 1 active_not_recruiting NCT04965688
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition No drug interventions treatment 2 recruiting NCT01953588
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery No drug interventions treatment 3 active_not_recruiting NCT00407888
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery No drug interventions treatment 2 completed NCT04571437
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) No drug interventions treatment 2 unknown_status NCT02186470
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer No drug interventions treatment Not Available active_not_recruiting NCT02269670
Phase II Study of Everolimus Beyond Progression No drug interventions treatment 2 terminated NCT03395899
Pre-operative Immunotherapy Combination Strategies in Breast Cancer No drug interventions other 2 completed NCT01100489
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer No drug interventions treatment 2 withdrawn NCT03886389
Breast Cancer Diet Intervention Study No drug interventions basic_science Not Available completed NCT04038489
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer treatment 2 withdrawn NCT00194792
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer treatment 2 terminated NCT01194440
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms No drug interventions supportive_care 2 completed NCT03285568
Patterns of Prescribing and Monitoring of Palbociclib No drug interventions Not Available Not Available completed NCT03719495
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer No drug interventions Not Available Not Available completed NCT05076695
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer No drug interventions treatment 2 recruiting NCT06062498
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT04504916
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) treatment 2 terminated NCT06525766
Adaptive Therapy With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer treatment 2 not_yet_recruiting NCT05607004
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer No drug interventions treatment 2 recruiting NCT06006910
Electronic Medical Record-Based Nudge to Reduce SLNB No drug interventions Not Available Not Available completed NCT06343987
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity No drug interventions treatment Not Available recruiting NCT06150898
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) No drug interventions other 2 not_yet_recruiting NCT01992952
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer treatment 1 / 2 unknown_status NCT01765049
Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor No drug interventions Not Available Not Available active_not_recruiting NCT02216786
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer treatment 2 unknown_status NCT02988986
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer treatment 2 completed NCT03250676
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer No drug interventions treatment 1 / 2 completed NCT02238808
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers No drug interventions treatment 2 active_not_recruiting NCT01984138
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy No drug interventions treatment 2 recruiting NCT00066690
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer treatment 3 active_not_recruiting NCT02820961
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer No drug interventions treatment 1 completed NCT02947685
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer No drug interventions treatment 3 active_not_recruiting NCT04727632
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial No drug interventions diagnostic 0 recruiting NCT02000375
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) No drug interventions treatment 2 terminated NCT01219699
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene No drug interventions treatment 1 completed NCT02409316
[18F]FES PET/CT in Endocrine Refractory Breast Cancer No drug interventions diagnostic 2 active_not_recruiting NCT02668666
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer No drug interventions treatment 2 completed NCT02414776
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy No drug interventions treatment 1 terminated NCT02823262
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older No drug interventions health_services_research Not Available terminated NCT01996046
FDG PET/CT in Breast Cancer Bone Mets No drug interventions Not Available Not Available active_not_recruiting NCT04360941
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer other 1 recruiting NCT05423730
Alcohol and Breast Cancer (ABC) Trial No drug interventions basic_science 0 completed NCT04985266
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer treatment 2 recruiting NCT01202591
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients treatment 1 / 2 completed NCT06407401
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer No drug interventions supportive_care 3 not_yet_recruiting NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04551495
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) No drug interventions treatment 2 active_not_recruiting NCT00828854
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing No drug interventions treatment 2 completed NCT03983954
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT04312347
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels No drug interventions treatment Not Available completed NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies No drug interventions treatment 1 recruiting NCT02580448
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) No drug interventions treatment 1 / 2 completed NCT06064812
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. No drug interventions treatment 1 recruiting NCT05525481
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer No drug interventions treatment 4 recruiting NCT04824014
4FMFES-PET Imaging of ER+ Advanced Breast Cancers No drug interventions diagnostic 2 recruiting NCT04920708
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression No drug interventions treatment 2 recruiting NCT05534438
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer No drug interventions treatment 2 recruiting NCT05101564
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT01361945
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer treatment 1 / 2 withdrawn NCT06176261
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs treatment 2 recruiting NCT04568616
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) treatment 2 recruiting NCT04660435
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer No drug interventions Not Available Not Available recruiting NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program treatment 1 recruiting NCT04504331
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer treatment 1 terminated NCT04886531
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers treatment 2 recruiting NCT05720260
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC treatment 2 recruiting NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer No drug interventions treatment 3 recruiting NCT04901299
Fulvestrant + Neratinib In Breast Cancer No drug interventions treatment 2 withdrawn NCT04276272
D4 Choline Breast PET/CT No drug interventions Not Available Not Available completed NCT05396612
Role of the Immune Environment in Response to Therapy in Breast Cancer No drug interventions Not Available Not Available recruiting NCT05512364
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) No drug interventions treatment 3 recruiting NCT06525675
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) Not Available Not Available active_not_recruiting NCT05163106
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole treatment 2 completed NCT05305924
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer treatment 2 recruiting NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. treatment 3 not_yet_recruiting NCT04738292
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) No drug interventions treatment 2 terminated NCT05826964
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer No drug interventions treatment 2 recruiting NCT00965939
An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients No drug interventions Not Available Not Available completed NCT02345772
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy No drug interventions treatment 1 / 2 terminated NCT04236310
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. No drug interventions treatment 2 unknown_status